Faster-acting insulin aspart showed a statistically significant reduction in HbA1c in type 1 diabetes and a comparable H

1) Russell-Jones D, et al. Double-blind mealtime faster-acting insulin aspart vs
insulin aspart in basal-bolus improves glycemic control in T1D: the onset(R) 1 trial.
Oral presentation at: 76th Scientific Sessions of the American Diabetes Association
(ADA). June 10-14, 2016; New Orleans, US.
2) Bowering K, et al. Faster-acting insulin aspart vs insulin aspart as part of
basal-bolus therapy improves postprandial glycemic control in uncontrolled T2D in the
double-blinded onset(R) 2 trial. Oral presentation at: 76th Scientific Sessions of the
American Diabetes Association (ADA). June 10-14, 2016; New Orleans, US.
3) Data on file. Novo Nordisk A/S; Bagsværd.
4) Data on file. Novo Nordisk A/S; Bagsværd.
5) Heise T, et al. Faster onset and greater early exposure and glucose-lowering effect
with faster-acting insulin aspart vs insulin aspart: a pooled analysis in subjects
with type 1 diabetes. Poster presented at: 76th Scientific Sessions of the American
Diabetes Association (ADA). June 10-14, 2016; New Orleans, US.
6) Nosek L, et al. Greater early glucose-lowering effect of faster-acting
insulin aspart is observed consistently from day to day. Poster presented at: 76th
Scientific Sessions of the American Diabetes Association (ADA). June 10-14, 2016; New
Orleans, US.